In terms of MCL-1 acting as a rational drug treatment therapeutic target, a genome-wide RNA interference screen identified MCL-1 as a key downstream survival factor in malignant glioma for therapeutic implications [49]. The gene discussed is MCL1; the disease is malignant glioma.